Kalaris Therapeutics (NASDAQ:KLRS) Receives "Sell (E)" Rating from Weiss Ratings

Key Points

• Kalaris Therapeutics has received a "Sell (E)" rating from Weiss Ratings, while other analysts have issued a mix of ratings including one Strong Buy and one Hold.
• The company's stock price opened at $6.59 and has experienced a 14.6% decline recently, with a 1-year high of $24.15 and a low of $2.14.
• Kalaris Therapeutics reported a quarterly loss of ($0.61) earnings per share, missing the consensus estimate, which might impact investor sentiment.

Kalaris Therapeutics (NASDAQ:KLRS - Get Free Report)'s stock had its "sell (e)" rating reiterated by analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Several other equities research analysts also recently issued reports on KLRS. Wall Street Zen upgraded Kalaris Therapeutics to a "hold" rating in a report on Friday, October 3rd. Raymond James Financial started coverage on Kalaris Therapeutics in a report on Tuesday, September 2nd. They issued a "strong-buy" rating for the company. Finally, Piper Sandler set a $3.00 price target on Kalaris Therapeutics and gave the stock a "neutral" rating in a report on Wednesday, July 23rd. One analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $3.00.

Kalaris Therapeutics Stock Down 14.6%

Shares of Kalaris Therapeutics stock opened at $6.59 on Wednesday. Kalaris Therapeutics has a 1 year low of $2.14 and a 1 year high of $24.15. The stock has a 50-day simple moving average of $4.07.

Kalaris Therapeutics (NASDAQ:KLRS - Get Free Report) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.10).

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Kalaris Therapeutics stock. XTX Topco Ltd acquired a new position in shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS - Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 24,234 shares of the company's stock, valued at approximately $65,000. XTX Topco Ltd owned approximately 0.13% of Kalaris Therapeutics as of its most recent filing with the Securities & Exchange Commission. 66.05% of the stock is currently owned by institutional investors and hedge funds.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.